...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Review of ZCC history

I think today RVX news release specifically stating  BETONMACE2 starting early next year is 100% indicative of a pending Zenith deal that could flow through to RVX in a soem sort of a large loan payable at a very favourable rate paid once BETONMACE2 trials are completed or stopped  early for efficacy,   I  expect a Zenith deal would be an upfront payment which could flow into RVX for trials financing, I don't think i am out in left field ....

Share
New Message
Please login to post a reply